MedTrace Logo

TGD001 Treatment in Thrombotic Microangiopathies

NCT07459114 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-03-09

No results posted yet for this study

Summary

This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or clinical diagnosis of an acute Thrombotic Microangiopathy (TMA) episode. The trial is an open-label, dose escalation and expansion basket trial.

Conditions

  • Thrombotic Microangiopathies
  • ITP Immune-Mediated Thrombocytopenia

Interventions

DRUG

TGD001

IV bolus administration

Sponsors & Collaborators

  • TargED Biopharmaceuticals B.V.

    lead INDUSTRY

Principal Investigators

  • Marielle Klein Hesselink, MD · TargED

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2028-05-31
Completion
2028-08-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07459114 on ClinicalTrials.gov